Edelblum Karen L, Sharon Gil, Singh Gurminder, Odenwald Matthew A, Sailer Anne, Cao Severine, Ravens Sarina, Thomsen Irene, El Bissati Kamal, McLeod Rima, Dong Chen, Gurbuxani Sandeep, Prinz Immo, Mazmanian Sarkis K, Turner Jerrold R
Department of Pathology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, New Jersey.
Department of Pathology, University of Chicago, Chicago, Illinois.
Cell Mol Gastroenterol Hepatol. 2017 Jun 10;4(2):285-297. doi: 10.1016/j.jcmgh.2017.06.001. eCollection 2017 Sep.
BACKGROUND & AIMS: Despite a prominent association, chronic intestinal barrier loss is insufficient to induce disease in human subjects or experimental animals. We hypothesized that compensatory mucosal immune activation might protect individuals with increased intestinal permeability from disease. We used a model in which intestinal barrier loss is triggered by intestinal epithelial-specific expression of constitutively active myosin light chain kinase (CA-MLCK). Here we asked whether constitutive tight junction barrier loss impacts susceptibility to enteric pathogens.
Acute or chronic or infection was assessed in CA-MLCK transgenic or wild-type mice. Germ-free mice or those lacking specific immune cell populations were used to investigate the effect of microbial-activated immunity on pathogen translocation in the context of increased intestinal permeability.
Acute and translocation across the epithelial barrier was reduced in CA-MLCK mice. This protection was due to enhanced mucosal immune activation that required CD4 T cells and interleukin 17A but not immunoglobulin A. The protective mucosal immune activation in CA-MLCK mice depended on segmented filamentous bacteria (SFB), because protection against early invasion was lost in germ-free CA-MLCK mice but could be restored by conventionalization with SFB-containing, not SFB-deficient, microbiota. In contrast, chronic infection was more severe in CA-MLCK mice, suggesting that despite activation of protective mucosal immunity, barrier defects ultimately result in enhanced disease progression.
Increased epithelial tight junction permeability synergizes with commensal bacteria to promote intestinal CD4 T-cell expansion and interleukin 17A production that limits enteric pathogen invasion.
尽管存在显著关联,但慢性肠道屏障丧失不足以在人类受试者或实验动物中诱发疾病。我们推测代偿性黏膜免疫激活可能保护肠道通透性增加的个体免于患病。我们使用了一种模型,其中肠道屏障丧失由组成型活性肌球蛋白轻链激酶(CA-MLCK)的肠道上皮特异性表达触发。在此,我们探讨组成型紧密连接屏障丧失是否会影响对肠道病原体的易感性。
在CA-MLCK转基因小鼠或野生型小鼠中评估急性或慢性感染。使用无菌小鼠或缺乏特定免疫细胞群体的小鼠,以研究微生物激活的免疫在肠道通透性增加情况下对病原体易位的影响。
CA-MLCK小鼠中急性感染和病原体穿过上皮屏障的易位减少。这种保护作用归因于增强的黏膜免疫激活,这需要CD4 T细胞和白细胞介素17A,但不需要免疫球蛋白A。CA-MLCK小鼠中保护性黏膜免疫激活依赖于分节丝状菌(SFB),因为无菌CA-MLCK小鼠中对早期感染的保护作用丧失,但通过用含SFB而非缺乏SFB的微生物群进行定殖可恢复。相反,CA-MLCK小鼠中的慢性感染更严重,这表明尽管保护性黏膜免疫被激活,但屏障缺陷最终导致疾病进展加剧。
上皮紧密连接通透性增加与共生细菌协同作用,促进肠道CD4 T细胞扩增和白细胞介素17A产生,从而限制肠道病原体入侵。